Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 587

1.

Advances in targeted therapies 2017.

Breedveld FC, Kalden JR, Smolen JS.

Clin Immunol. 2018 Jan;186:1-2. doi: 10.1016/j.clim.2018.01.007. Epub 2018 Jan 31. No abstract available.

PMID:
29378299
2.

Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.

Kalden JR, Schulze-Koops H.

Nat Rev Rheumatol. 2017 Nov 21;13(12):707-718. doi: 10.1038/nrrheum.2017.187. Review.

PMID:
29158574
3.

Advances in targeted therapy.

Breedveld FC, Kalden JR, Smolen JS.

Rheumatology (Oxford). 2016 Dec;55(suppl 2):ii1-ii2. No abstract available.

PMID:
27856653
4.

[Erratum to: Biologics].

Kalden JR.

Z Rheumatol. 2016 Dec;75(10):998. German. No abstract available.

PMID:
27752757
5.

Emerging Therapies for Rheumatoid Arthritis.

Kalden JR.

Rheumatol Ther. 2016 Jun;3(1):31-42. doi: 10.1007/s40744-016-0032-4. Epub 2016 Jun 3. Review.

6.

The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016.

Winthrop KL, Strand V, van der Heijde DM, Mease PJ, Crow MK, Weinblatt M, Bathon JM, Buch MH, Burmester GR, Dougados M, Kay J, Mariette X, Breedveld FC, Kalden JR, Smolen JS, Furst DE.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4 Suppl 98):69-76. Epub 2016 Aug 3.

7.

[Biologics].

Kalden JR.

Z Rheumatol. 2016 Aug;75(6):604-10. doi: 10.1007/s00393-016-0122-2. Review. German. No abstract available. Erratum in: Z Rheumatol. 2016 Oct 11;:.

PMID:
27365024
8.

[Pathogenic cells of rheumatic inflammation as the target of modern therapies].

Kalden JR.

Z Rheumatol. 2015 Feb;74(1):8-13. doi: 10.1007/s00393-014-1437-5. Review. German.

PMID:
25676124
9.

Induction of proliferation and pro-inflammatory cytokine production in rheumatoid arthritis peripheral blood mononuclear cells by a 65 KDa chondrocyte membrane-specific, constitutive target autoantigen (CH65).

Alsalameh RJ, Casey RC, Mollenhauer J, Kalden JR, Burmester GR, Alsalameh SM.

Int J Rheum Dis. 2017 Sep;20(9):1132-1141. doi: 10.1111/1756-185X.12167. Epub 2013 Oct 16.

PMID:
24131486
10.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.

Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Rubbert-Roth A, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop KL.

Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii2-34. doi: 10.1136/annrheumdis-2013-203348. No abstract available.

PMID:
23532441
11.

Advances in targeted therapies XIV.

Breedveld FC, Kalden JR, Smolen JS.

Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii1. doi: 10.1136/annrheumdis-2012-202416. No abstract available.

PMID:
23532438
12.

Advances in targeted therapies XIII.

Breedveld FC, Kalden JR, Smolen JS.

Ann Rheum Dis. 2012 Apr;71 Suppl 2:i1. doi: 10.1136/annrheumdis-2011-201013. No abstract available.

PMID:
22460135
13.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.

Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K.

Ann Rheum Dis. 2012 Apr;71 Suppl 2:i2-45. doi: 10.1136/annrheumdis-2011-201036. No abstract available.

PMID:
22460137
14.

Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.

Wissniowski TT, Meister S, Hahn EG, Kalden JR, Voll R, Ocker M.

Int J Oncol. 2012 May;40(5):1581-9. doi: 10.3892/ijo.2012.1337. Epub 2012 Jan 18.

PMID:
22266985
15.

[University contribution to implementation of the treat-to-target concept in rheumatology].

Kalden JR, Müller-Ladner U, Schmidt RE.

Z Rheumatol. 2011 Oct;70(8):651-5. doi: 10.1007/s00393-011-0762-1. Review. German.

PMID:
21979316
16.

[Strategies for improved healthcare of people with the endemic disease rheumatism exemplified by rheumatoid arthritis].

Kalden JR, Burkhardt H, Buss B, Donhauser-Gruber U, Erstling U, Gromnica-Ihle E, Karberg K, Karger T, Kneitz CH, Krause A, Krüger K, Lorenz HM, Müller-Ladner U, Rubbert-Roth A, Steffens-Korbanka P, Tony HP, Wendler J, Wollenhaupt J, Burmester G.

Z Rheumatol. 2011 Oct;70(8):641-50. doi: 10.1007/s00393-011-0763-0. Review. German.

PMID:
21979315
17.

[Treat to target (T2T)].

Kalden JR, Burmester GR, Schmidt RE.

Z Rheumatol. 2011 Oct;70(8):639-40. doi: 10.1007/s00393-010-0727-9. German. No abstract available.

PMID:
21979314
18.

Advances in rheumatology: new targeted therapeutics.

Tak PP, Kalden JR.

Arthritis Res Ther. 2011 May 25;13 Suppl 1:S5. doi: 10.1186/1478-6354-13-S1-S5. Review.

19.

Anti-TNF therapy: what have we learned in 12 years?

Kalden JR.

Arthritis Res Ther. 2011 May 25;13 Suppl 1:S1. doi: 10.1186/1478-6354-13-S1-S1. No abstract available.

20.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.

Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K.

Ann Rheum Dis. 2011 Mar;70 Suppl 1:i2-36. doi: 10.1136/ard.2010.146852. No abstract available.

PMID:
21339216
21.

Advances in targeted therapies XII. Preface.

Breedveld FC, Kalden JR, Smolen JS.

Ann Rheum Dis. 2011 Mar;70 Suppl 1:i1. doi: 10.1136/ard.2010.141044. No abstract available.

PMID:
21339210
22.

Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study.

Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, Sardu C, Ujfalussy I, Scarpa R, Marchesoni A, Taylor WJ, Spadaro A, Fernàndez-Sueiro JL, Salvarani C, Kalden JR, Lubrano E, Carneiro S, Desiati F, Flynn JA, D'Angelo S, Vacca A, VAN Kuijk AW, Catanoso MG, Gruenke M, Peluso R, Parsons WJ, Ferrara N, Contu P, Helliwell PS, Mease PJ; GRAPPA 3PPsA Study Group.

J Rheumatol. 2011 May;38(5):898-903. doi: 10.3899/jrheum.100857. Epub 2011 Feb 15.

PMID:
21324965
23.

Specific removal of C-reactive protein by apheresis in a porcine cardiac infarction model.

Slagman AC, Bock C, Abdel-Aty H, Vogt B, Gebauer F, Janelt G, Wohlgemuth F, Morgenstern R, Yapici G, Puppe A, Modersohn D, Mans D, Jerichow T, Ott S, Kunze R, Schrödl W, Janko C, Hermann M, Kalden JR, Kern P, Parsch H, Kirschfink M, Schulz-Menger J, Röttgen R, Unger JK, Frei U, Schindler R, Möckel M, Sheriff A.

Blood Purif. 2011;31(1-3):9-17. doi: 10.1159/000320763. Epub 2010 Dec 7.

PMID:
21135544
24.

A glimpse into the future: recombinant proteins and small molecules for targeted therapies in rheumatic diseases.

Kalden JR, Braun J.

Clin Exp Rheumatol. 2009 Jul-Aug;27(4 Suppl 55):S168-70.

PMID:
19822067
25.

Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis.

Braun J, Kalden JR.

Clin Exp Rheumatol. 2009 Jul-Aug;27(4 Suppl 55):S164-7.

PMID:
19822066
26.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.

Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Braun J, Bresnihan B, Burmester GR, De Benedetti F, Dörner T, Emery P, Gibofsky A, Kavanaugh A, Kirkham B, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH, Winthrop K.

Ann Rheum Dis. 2010 Jan;69 Suppl 1:i2-29. doi: 10.1136/ard.2009.123885. No abstract available. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
19995740
27.

Advances in targeted therapies XI.

Breedveld FC, Kalden JR, Smolen JS.

Ann Rheum Dis. 2010 Jan;69 Suppl 1:i1. doi: 10.1136/ard.2009.120253. No abstract available.

PMID:
19995739
28.

Stress of different types increases the proinflammatory load in rheumatoid arthritis.

Straub RH, Kalden JR.

Arthritis Res Ther. 2009;11(3):114. doi: 10.1186/ar2712. Epub 2009 Jun 17.

29.

Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus.

Muñoz LE, Janko C, Grossmayer GE, Frey B, Voll RE, Kern P, Kalden JR, Schett G, Fietkau R, Herrmann M, Gaipl US.

Arthritis Rheum. 2009 Jun;60(6):1733-42. doi: 10.1002/art.24535.

30.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.

Furst DE, Keystone EC, Kirkham B, Kavanaugh A, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Burmester GR, Braun J, Emery P, Winthrop K, Bresnihan B, De Benedetti F, Dörner T, Gibofsky A, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH.

Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii2-25. doi: 10.1136/ard.2008.100834. No abstract available. Erratum in: Ann Rheum Dis. 2009 Mar;68(3):452. Kavanaugh, A [added].

PMID:
19022808
31.

Advances in targeted therapies X. Preface.

Breedveld FC, Kalden JR, Smolen JS.

Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii1. doi: 10.1136/ard.2008.098806. No abstract available.

PMID:
19022807
32.

Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE.

Urbonaviciute V, Fürnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F, Bianchi ME, Kirschning C, Wagner H, Manfredi AA, Kalden JR, Schett G, Rovere-Querini P, Herrmann M, Voll RE.

J Exp Med. 2008 Dec 22;205(13):3007-18. doi: 10.1084/jem.20081165. Epub 2008 Dec 8.

33.

Inhibition of TNF-alpha reduces transplant arteriosclerosis in a murine aortic transplant model.

Wollin M, Abele S, Bruns H, Weyand M, Kalden JR, Ensminger SM, Spriewald BM.

Transpl Int. 2009 Mar;22(3):342-9. doi: 10.1111/j.1432-2277.2008.00802.x. Epub 2008 Dec 3.

34.

Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in an open-label clinical trial.

Kalden JR, Nüsslein HG, Wollenhaupt J, Burmester GR, Krüger K, Antoni C.

Clin Exp Rheumatol. 2008 Sep-Oct;26(5):834-40.

PMID:
19032816
35.

Information and participation in decision-making about treatment: a qualitative study of the perceptions and preferences of patients with rheumatoid arthritis.

Schildmann J, Grunke M, Kalden JR, Vollmann J.

J Med Ethics. 2008 Nov;34(11):775-9. doi: 10.1136/jme.2007.023705.

PMID:
18974408
36.

The role of high-mobility group box 1 protein in the pathogenesis of autoimmune diseases.

Voll RE, Urbonaviciute V, Fürnrohr B, Herrmann M, Kalden JR.

Curr Rheumatol Rep. 2008 Oct;10(5):341-2. No abstract available.

PMID:
18817635
37.

Treatment of acquired thrombotic thrombocytopenic purpura (TTP) with plasma infusion plus rituximab.

Hagel S, Jantsch J, Budde U, Kalden JR, Eckardt KU, Veelken R.

Thromb Haemost. 2008 Jul;100(1):151-3. doi: 10.1160/TH08-02-0089. No abstract available.

PMID:
18612551
38.

Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade.

Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Aletaha D, Baker D, Han J, Bala M, St Clair EW; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group.

Ann Rheum Dis. 2009 Jun;68(6):823-7. doi: 10.1136/ard.2008.090019. Epub 2008 Jul 1. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
18593759
39.

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.

Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA, Voll RE.

Nat Med. 2008 Jul;14(7):748-55. doi: 10.1038/nm1763. Epub 2008 Jun 8.

PMID:
18542049
40.

Remission of demyelinating polyneuropathy with immunoadsorption, low dose corticosteroids and anti-CD20 monoclonal antibody.

Rech J, Hueber AJ, Kallert S, Leipe J, Kalden JR, Beck M, Schett G, Schulze-Koops H.

Ther Apher Dial. 2008 Jun;12(3):205-8. doi: 10.1111/j.1744-9987.2008.00573.x.

PMID:
18503697
41.

Increased cortisol relative to adrenocorticotropic hormone predicts improvement during anti-tumor necrosis factor therapy in rheumatoid arthritis.

Straub RH, Pongratz G, Cutolo M, Wijbrandts CA, Baeten D, Fleck M, Atzeni F, Grunke M, Kalden JR, Schölmerich J, Lorenz HM, Tak PP, Sarzi-Puttini P.

Arthritis Rheum. 2008 Apr;58(4):976-84. doi: 10.1002/art.23385.

42.

Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).

Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman DD, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen JS.

J Rheumatol. 2008 May;35(5):869-76. Epub 2008 Mar 15.

PMID:
18381786
43.

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status.

van der Bijl AE, Breedveld FC, Antoni CE, Kalden JR, Kary S, Burmester GR, Beckmann C, Unnebrink K, Kupper H.

Clin Rheumatol. 2008 Aug;27(8):1021-8. doi: 10.1007/s10067-008-0866-4. Epub 2008 Mar 19.

44.

Anti-HLA-DR-triggered monocytes mediate in vitro T cell anergy.

Kriegel MA, Adam-Klages S, Gabler C, Blank N, Schiller M, Scheidig C, Kalden JR, Lorenz HM.

Int Immunol. 2008 Apr;20(4):601-13. doi: 10.1093/intimm/dxn019. Epub 2008 Feb 28.

PMID:
18310062
45.

High mobility group box 1 in the pathogenesis of inflammatory and autoimmune diseases.

Voll RE, Urbonaviciute V, Herrmann M, Kalden JR.

Isr Med Assoc J. 2008 Jan;10(1):26-8. Review.

46.

IgG autoantibodies bound to surfaces of necrotic cells and complement C4 comprise the phagocytosis promoting activity for necrotic cells of systemic lupus erythaematosus sera.

Grossmayer GE, Munoz LE, Weber CK, Franz S, Voll RE, Kern PM, Kalden JR, Schett G, Herrmann M, Gaipl US.

Ann Rheum Dis. 2008 Nov;67(11):1626-32. doi: 10.1136/ard.2007.081828. Epub 2007 Dec 28.

PMID:
18165321
47.

Hypothesis: human serum-borne albumin bound lipids promote cellular survival after apoptosis induction by a variety of stimuli.

Schiller M, Franz S, Heyder P, Voll RE, Gaipl US, Lorenz HM, Kalden JR, Herrmann M.

Apoptosis. 2008 Feb;13(2):319-28.

PMID:
18080861
48.

Biological agents in rheumatoid arthritis: which ones could be used in combination?

Lorenz M, Kalden JR.

BioDrugs. 1998 Apr;9(4):303-24.

PMID:
18020567
49.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, Emery P, Keystone EC, Schiff MH, Mease P, van Riel PL, Fleischmann R, Weisman MH, Weinblatt ME.

Ann Rheum Dis. 2007 Nov;66 Suppl 3:iii2-22. Review. No abstract available. Erratum in: Ann Rheum Dis. 2008 Feb;67(2):280.

50.

Microparticles stimulate the synthesis of prostaglandin E(2) via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1.

Jüngel A, Distler O, Schulze-Horsel U, Huber LC, Ha HR, Simmen B, Kalden JR, Pisetsky DS, Gay S, Distler JH.

Arthritis Rheum. 2007 Nov;56(11):3564-74.

Supplemental Content

Loading ...
Support Center